Market Research Logo

Global Endocrinology Drugs Market 2016-2020

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Key buying criteria
    • Table Key buying criteria for endocrinology drugs
  • Pipeline portfolio
    • Table Pipeline portfolio: Global diabetes drugs market
    • Table Pipeline portfolio: Global thyroid disorder drugs market
    • Table Pipeline portfolio: Global human growth hormone drugs market
    • Table Pipeline portfolio: Global testosterone drugs market
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global endocrinology drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by application
    • Table Market segmentation of global endocrinology drugs market by application
    • Table Global endocrinology drugs market: YoY growth and revenue based on application 2015-2020
  • Global diabetes drugs market
    • Introduction
      • Table Global diabetes market by type of disease 2015
      • Table Top-selling diabetes drugs based on sales 2015 ($ billions)
      • Table Market share of global diabetes drugs in global pharmaceutical market 2015
    • Market overview
      • Table Global diabetes drugs market 2015-2020 ($ billions)
    • Market drivers
    • Market challenges
    • Market trends
    • Vendor analysis of global diabetes drugs market
      • Table Market share analysis of vendors in global diabetes drugs market
  • Global testosterone replacement therapy market
    • Introduction
    • Market overview
      • Table Global testosterone replacement therapy market 2015-2020 ($ billions)
    • Market drivers
    • Market challenges
    • Market trends
    • Vendor analysis of global testosterone replacement therapy market
  • Global human growth hormone market
    • Introduction
    • Market overview
      • Table Global human growth hormone market 2015-2020 ($ billions)
    • Market drivers
    • Market challenges
    • Market trends
    • Vendor analysis of global human growth hormone market
  • Global thyroid hormone disorder drugs market
    • Market overview
      • Table Global human growth hormone market 2015-2020 ($ billions)
    • Market drivers
    • Market challenges
    • Market trends
    • Vendor analysis of global thyroid disorder drugs market
  • Geographical segmentation
    • Global endocrinology drugs market by geographical segmentation 2015-2020
      • Table Segmentation of global endocrinology drugs market based on geography 2015
      • Table Global endocrinology drugs market revenue by geography 2015-2020 ($ billions)
      • Table Global endocrinology drugs market by geography 2015-2020
    • Endocrinology drugs market in Americas
      • Table Endocrinology drugs market in Americas 2015-2020 ($ billions)
    • Endocrinology drugs market in EMEA
      • Table Endocrinology drugs market in EMEA 2015-2020 ($ billions)
    • Endocrinology drugs market in APAC
      • Table Endocrinology drugs market in APAC 2015-2020 ($ billions)
      • Table Global endocrinology drugs market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in prevalence of endocrine hormone-related diseases
    • Promising drug pipeline
    • Advances in drug delivery technology
    • Stringent regulatory conditions for biosimilar drugs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Generic erosion
    • Side effects and associated risks
    • Rising concerns in scientific community
    • Low diagnosis rate
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Development of drugs with novel mechanism and technologies
    • Strategic alliances and M&A
    • Increased awareness
    • Increase in outsourcing
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2015
      • Table Revenues from the sales of top seven products in type 2 diabetes market 2012-2014 ($ billions)
    • Novo Nordisk
      • Table Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
      • Table Novo Nordisk: Geographical segmentation of human insulins 2015
      • Table Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
      • Table Geographical segmentation of Levemir 2015
      • Table Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
      • Table Novo Nordisk: Revenue of NovoLog/NovoRapid by geography 2015
      • Table Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
      • Table Novo Nordisk: Geographical split of revenues of NovoMix 2015
      • Table Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
      • Table Novo Nordisk: YoY revenue and growth rate of Victoza 2013-2015 ($ billions)
      • Table Geographical segmentation of Victoza 2015
      • Table Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and PrandiMet 2012-2014 ($ millions)
      • Table Novo Nordisk: YoY growth rate and revenue of Norditropin 2013-2015 ($ billions)
      • Table Novo Nordisk: Revenue of Norditropin by geography 2015
      • Table Novo Nordisk: Key takeaways
    • Sanofi
      • Table Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
      • Table Sanofi: Geographical segmentation of Lantus by revenue 2015
      • Table Sanofi: YoY revenue and growth rate of Amaryl 2013-2015 ($ millions)
      • Table Sanofi: Amaryl geographical segmentation by revenue 2015
      • Table Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ million)
      • Table Sanofi: Geographical segmentation of Toujeo by revenue 2015 (%)
      • Table Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
      • Table Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
      • Table Sanofi: Key takeaways
    • Merck
      • Table Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions)
      • Table Merck: Key takeaways
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
      • Table Eli Lilly: YoY revenue and growth rate of Trajenta and Jentadueto 2012-2015 ($ billions)
      • Table Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)
      • Table Eli Lilly: Trulicity geographical segmentation by revenue 2015
      • Table Eli Lilly: Key takeaways
    • AstraZeneca
      • Table AstraZeneca: YoY revenue and growth rate of Farxiga 2013-2015 ($ millions)
      • Table AstraZeneca: Geographical segmentation of Farxiga/Forxiga by revenue 2015
      • Table AstraZeneca: YoY revenue and growth rate of Byetta 2013-2015 ($ million)
      • Table AstraZeneca: YoY revenue and growth rate of Bydureon 2013-2015 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Kombiglyze/Komboglyze/Onglyza 2013-2015 ($ millions)
      • Table AstraZeneca: Key takeaways
    • AbbVie
      • Table AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ millions)
      • Table AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ millions)
      • Table AbbVie: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

About Endocrinology Drugs

Endocrinology deals with the study of the endocrine system, including the biochemical and physiological functions of the hormones, cells, and tissues of the endocrine glands. Endocrine disorders can be broadly subdivided into three categories: endocrine gland hyposecretion, which causes hormone deficiency, endocrine gland hypersecretion, which causes excess hormone secretion, and tumors in the endocrine gland. The endocrine disorders considered for the present report include diabetes, human growth hormone deficiency, thyroid disorders, and male hypogonadism.

Technavio’s analysts forecast the global endocrinology drugs market to grow at a CAGR of 6.69% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global endocrinology drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat and prevent type 1 and type 2 diabetes, human growth hormone deficiency, hypogonadism, and thyroid gland disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Endocrinology Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AbbVie Inc.
  • AstraZeneca PLC
  • Eli Lilly and Co.
  • Merck & Co
  • Novo Nordisk AS
  • Sanofi SA
Other prominent vendors
  • Acerus Pharmaceuticals
  • Acrux DDS
  • Adocia
  • Æterna Zentaris
  • Akros Pharma
  • Allergan
  • Amgen
  • Antares Pharma
  • Ascendis Pharma
  • Astellas Pharma
  • Baxalta
  • Bayer HealthCare Pharmaceuticals
  • BHV Pharma
  • Biocon
  • Biodel
  • Boehringer Ingelheim
  • ChipScreen Biosciences
  • Clarus Therapeutics
  • ConjuChem
  • Critical Pharmaceuticals
  • CureDm
  • CymaBay Therapeutics
  • Daiichi Sankyo
  • Dance Biopharm
  • DiaMedica
  • Diamyd Therapeutics
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dong-A ST
  • Eisai
  • Elcelyx Therapeutics
  • Endo Pharmaceuticals
  • Exsulin
  • Ferring Pharmaceuticals
  • Gan & Lee Pharmaceuticals
  • Genentech
  • Generex
  • Genexine
  • Genfit
  • GSK
  • HanAll BioPharma
  • Hanmi Pharmaceutical
  • Hua Medicine
  • ILTOO Pharma
  • Intarcia Therapeutics
  • InteKrin Therapeutics
  • Intrexon
  • Ionis Pharmaceuticals
  • Ipe
  • Islet Sciences
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Juniper Pharmaceuticals
  • Kadmon Corporation
  • Kamada
  • KinDex Pharmaceuticals
  • Kissei Pharmaceutical
  • Kotobuki
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • Ligand Pharmaceuticals
  • Lipocine
  • Living Cell Technologies
  • MacroGenics
  • MannKind
  • MedImmune
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • MetP Pharma
  • Mitsubishi Tanabe Pharma
  • Mylan
  • NGM Biopharmaceuticals
  • Novartis
  • NuSirt Biopharma
  • OPKO Biologics
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Peptron
  • Perle Biosciences
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Poxel
  • ProStrakan Group
  • REGiMMUNE
  • Repros Therapeutics
  • Roche
  • Sanwa Kagaku Kenkyusho
  • Sirona Biochem
  • Strongbridge Biopharma
  • Takeda Pharmaceuticals
  • TesoRx Pharma
  • Teva Pharmaceutical
  • Theracos
  • Theratechnologies
  • Toleranzia
  • Tolerion
  • Transition Therapeutics
  • VeroScience
  • Versartis
  • vTv Therapeutics
  • XBiotech
  • Xeris Pharmaceuticals
  • XOMA
Market driver
  • Increase in prevalence of endocrine hormone-related diseases
  • For a full, detailed list, view our report
Market challenge
  • Generic erosion
  • For a full, detailed list, view our report
Market trend
  • Increase in outsourcing
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Endocrinology Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Endocrinology Drugs Market: AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, and Sanofi SA.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, and XOMA.

Commenting on the report, an analyst from Technavio’s team said: “As vendors are facing the problem of a decline in venture capital investment, they are increasingly following the strategy of outsourcing. Different parts of research such as product characterization testing and toxicology testing are outsourced to third-party research organizations. Similarly, some vendors outsource the pharmaceutical product manufacturing or the entire manufacturing process to contract manufacturing organizations. This reduces the operational costs, as most companies do not have to maintain expensive R&D laboratories and scientists. Pharmaceutical companies rely on the contract manufacturing organizations based in India, China, Russia, and Eastern Europe to manufacture and process their products.”

According to the report, the increase or decrease in the release of endocrine hormones leads to disorders such as diabetes, hypogonadism, hypothyroidism, and hyperthyroidism. The prevalence of diabetes is rising because of obesity, unhealthy diet, and lack of physical activity among individuals. The prevalence of hypogonadism also increases in men with diabetes, human immunodeficiency virus (HIV), chronic obstructive pulmonary disease, heart or renal disease, or in individuals who are on opiate or glucocorticoid therapy. Thus, the increase in the prevalence of these diseases will lead to the increase in the intake of medications, propelling the market growth.

Further, the report states that the patent expiry of major approved drugs is expected to impact the market adversely and slow down its growth during the forecast period.

Companies Mentioned

AbbVie Inc., AstraZeneca PLC, Eli Lilly and Co., Merck & Co, Novo Nordisk AS, Sanofi SA, Acerus Pharmaceuticals, Acrux DDS, Adocia, Æterna Zentaris, Akros Pharma, Allergan, Amgen, Antares Pharma, Ascendis Pharma, Astellas Pharma, Baxalta, Bayer HealthCare Pharmaceuticals, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, ChipScreen Biosciences, Clarus Therapeutics, ConjuChem, Critical Pharmaceuticals, CureDm, CymaBay Therapeutics, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Endo Pharmaceuticals, Exsulin, Ferring Pharmaceuticals, Gan & Lee Pharmaceuticals, Genentech, Generex, Genexine, Genfit, GSK, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, ILTOO Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Ipe, Islet Sciences, Janssen Pharmaceuticals, Japan Tobacco, Juniper Pharmaceuticals, Kadmon Corporation, Kamada, KinDex Pharmaceuticals, Kissei Pharmaceutical, Kotobuki, Lexicon Pharmaceuticals, LG Life Sciences, Ligand Pharmaceuticals, Lipocine, Living Cell Technologies, MacroGenics, MannKind, MedImmune, Melior Pharmaceuticals, Metabolic Solutions Development Company, MetP Pharma, Mitsubishi Tanabe Pharma, Mylan, NGM Biopharmaceuticals, Novartis, NuSirt Biopharma, OPKO Biologics, Oramed Pharmaceuticals, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, ProStrakan Group, REGiMMUNE, Repros Therapeutics, Roche, Sanwa Kagaku Kenkyusho, Sirona Biochem, Strongbridge Biopharma, Takeda Pharmaceuticals, TesoRx Pharma, Teva Pharmaceutical, Theracos, Theratechnologies, Toleranzia, Tolerion, Transition Therapeutics, VeroScience, Versartis, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;